Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094059 | 0.83 | — | — | |
| SCHEMBL710076 | 0.79 | ALDH1A1 (0.47) | ALDH1A1HIF1A | |
| SCHEMBL1086344 | 0.77 | HSD17B10 (0.34) | ALDH1A1 | |
| SCHEMBL15121292 | 0.75 | MAPK1 (0.33) | ALDH1A1 | |
| SCHEMBL3456576 | 0.75 | VCAM1 (0.31) | — | |
| SCHEMBL2767392 | 0.71 | — | — | |
| SCHEMBL6811410 | 0.71 | — | — | |
| SCHEMBL2973487 | 0.71 | KIF11 (0.30) | — | |
| SCHEMBL423990 | 0.70 | — | — | |
| SCHEMBL2765842 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-11-08 | — | — | US | claimed |
| EP-1848713-A2 | AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-31 | — | — | EP | claimed |
| EP-1416931-B1 | INHIBITORS OF POLYQ-AGGREGATION | MAX PLANCK GESELLSCHAFT (DE) | 2007-06-13 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060116407-A1 | Amide derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-01 | — | — | US | claimed |
| WO-2006053778-A2 | AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-26 | — | — | WO | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | claimed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | claimed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1529046-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2004014905-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | ALDH1A1 2251/4885HIF1A 2015/4885 |
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | HTT, ATXN2, ATXN2L | ALDH1A1 3178/4885HIF1A 3830/4885 |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | HTT, ATXN2, ATXN2L | ALDH1A1 3178/4885HIF1A 3830/4885 |
| US-20060116407-A1 | Amide derivatives | GLS, SDHA, GLS2 | ALDH1A1 71/4885HIF1A 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.